NCT03985384View on ClinicalTrials.gov

Semaglutide Treatment On Coronary Progression

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions
Type 2 DiabetesCoronary Artery Disease
Interventions
DRUG

Semaglutide 2 MG/1.5 ML Subcutaneous Solution

Semaglutide 2 MG/1.5 ML Subcutaneous Solution

DRUG

Placebo

Placebo 1.5 ml, pen-injector for SC injection.

Trial Locations (1)

90502

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance

All Listed Sponsors
lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT03985384 - Semaglutide Treatment On Coronary Progression | Biotech Hunter | Biotech Hunter